Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2025)

Crinetics Pharmaceuticals (CRNX) has 8 years of Equity Average data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, Equity Average fell 4.33% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 4.33%, while the annual FY2025 figure was $1.2 billion, 24.3% up from the prior year.
  • Equity Average reached $1.0 billion in Q4 2025 per CRNX's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.3 billion in Q1 2025 and bottomed at $159.2 million in Q1 2021.
  • Average Equity Average over 5 years is $589.8 million, with a median of $384.9 million recorded in 2022.
  • Peak YoY movement for Equity Average: dropped 22.46% in 2023, then skyrocketed 219.15% in 2024.
  • A 5-year view of Equity Average shows it stood at $262.8 million in 2021, then increased by 27.05% to $333.8 million in 2022, then soared by 62.78% to $543.4 million in 2023, then soared by 98.53% to $1.1 billion in 2024, then dropped by 4.33% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $1.0 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.